11-12 September 2018 //  Lancaster Royal Hotel, London


Steven Howe

Dr Steven Howe

Head, Process Research, Cell & Gene Therapy Platform CMC, GlaxoSmithKline

Steven Howe is Head of Process Research, Cell and Gene Therapy Platform Technology and Sciences.

He gained his BSc Honours degree in Biology at the University of Bristol, and subsequently earned his PhD at Imperial College, London, investigating the potential of artificial chromosomes for gene therapy.

Steven carried out his postdoctoral studies at the UCL Institute of Child Health, London, contributing to successful gene therapy clinical trials led by Prof. Adrian Thrasher, assessing gene therapy approaches and technologies for different disorders of the immune system. Here, he formed a group to investigate and improve ex vivo hematopoietic stem gene therapy using retroviral vectors.

In his current position at GlaxoSmithKline, he leads a team responsible for delivering improvements to viral vectors and their production, alongside development of processes for cell isolation, characterisation and transduction.  As well as early research, this team assists in the progression of therapies in the pipeline through to medicinal product approval.


2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad